预测前列腺癌放疗剂量反应:在随机III期NRG/RTOG 0126和SAKK 09/10试验中验证放疗特征
在SAKK 09/10(生化复发前列腺癌,挽救放疗64 Gy vs 70 Gy)和NRG/RTOG 0126(中危前列腺癌,根治性放疗70.2 Gy vs 79.2 Gy)中验证PORTOS。SAKK 09/10中PORTOS与治疗臂对临床无进展生存的交互作用显著,仅高PORTOS组从剂量递增中获益;NRG/RTOG 0126中平均和高三分位PORTOS组从剂量递增中显著获益。PORTOS与临床病理变量无强关联。
要点
- SAKK 09/10中PORTOS与治疗臂对临床无进展生存的交互作用有统计学意义,仅高PORTOS组从剂量递增中获益。
- NRG/RTOG 0126中低三分位PORTOS组Phoenix生化失败无差异,平均和高三分位组剂量递增显著获益。
- PORTOS与临床病理变量无强关联,但与免疫特征强关联。
核心结论
- 在SAKK 09/10和RTOG 0126随机对照试验中,PORTOS可能识别出从剂量递增中获益的患者亚组,该亚组无法通过临床病理或预后变量识别。
- 这些结果提示PORTOS可作为放疗反应的临床预测指标。
研究设计与样本
- SAKK 09/10将生化复发前列腺癌患者随机分配至挽救放疗64 Gy vs 70 Gy。
- NRG/RTOG 0126将中危前列腺癌患者随机分配至根治性放疗70.2 Gy vs 79.2 Gy。
- 在SAKK 09/10和NRG/RTOG 0126中评估PORTOS,组织质控合格者分别为n=226和n=215。
- SAKK 09/10按已发表术后分组评估PORTOS,NRG/RTOG 0126按三分位评估(活检样本和根治性放疗患者未确定截断值)。
- 分析真实世界数据集42 407例前列腺切除样本和31 107例活检样本的临床和分子相关性。
主要发现
- SAKK 09/10中PORTOS(较低 vs 较高)与治疗臂对临床无进展生存的交互作用有统计学意义,仅高PORTOS组从剂量递增中获益。
- NRG/RTOG 0126中低三分位PORTOS组Phoenix生化失败无差异,平均和高三分位PORTOS组剂量递增对Phoenix生化失败有显著获益。
- 交互检验表明高与低PORTOS组间剂量递增获益有显著差异。
- PORTOS在两个试验或大型真实世界数据集中与临床病理变量无强关联。
- 真实世界数据集中PORTOS与缺氧特征呈弱关联,与免疫特征和亚型强关联。
关键数值与推荐
- SAKK 09/10中PORTOS与治疗臂对临床无进展生存的交互作用有统计学意义。
- NRG/RTOG 0126中低三分位PORTOS组Phoenix生化失败无差异,平均和高三分位组剂量递增显著获益。
- 交互检验显示高与低PORTOS组间剂量递增获益有显著差异。
临床怎么用
- 原文结论提示PORTOS可能识别从剂量递增中获益的患者亚组,并可能作为放疗反应的临床预测指标。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The SAKK 09/10 trial randomized biochemically recurrent prostate cancer patients to salvage radiation 64 Gy versus 70 Gy, and the NRG/RTOG 0126 randomized intermediate-risk prostate cancer patients to definitive radiation 70.2 Gy versus 79.2 Gy. We investigated a previously developed Post-Operative Radiation Therapy Outcomes Score (PORTOS) to identify preferential benefit from radiation dose escalation (DE). MATERIALS AND METHODS: PORTOS was evaluated in patients enrolled in SAKK 09/10 and NRG/RTOG 0126 with available tissue that passed quality control (n = 226, 215). PORTOS was evaluated in the published post-operative groups in SAKK 09/10 and in tertiles in NRG/RTOG 0126 as cut-offs had not been established for biopsy samples and definitive radiation patients. Clinical and molecular correlates in a real-world dataset of 42 407 prostatectomy and 31 107 biopsy samples were also analyzed. RESULTS: In SAKK 09/10, the biomarker-treatment interaction was statistically significant between PORTOS (lower versus higher) and treatment arm for clinical progression-free survival. Only patients in the higher PORTOS group benefited from DE. In NRG/RTOG 0126, in patients with a lower tertile PORTOS, there was no difference in Phoenix biochemical failure (BF). However, for patients in the average and higher tertile PORTOS range, there was a significant benefit for DE for Phoenix BF. An interaction test indicated a significant difference in benefit for DE between higher and lower PORTOS groups. PORTOS was not strongly associated with clinicopathological variables in either trial or the large real-world dataset. In the latter, PORTOS was modestly associated with hypoxia signatures and strongly associated with immune signatures and subtypes. CONCLUSION: In the SAKK 09/10 and RTOG 0126 randomized controlled trials, we demonstrated that PORTOS can potentially identify a subset of patients who benefit from DE, a subgroup that cannot be identified using clinicopathological or prognostic variables. These results suggest that PORTOS could be used clinically as a predictor of radiation response.
引用
- Dal Pra A, Ghadjar P, Ryu HM, et al. Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials. Ann Oncol. 2025. PMID: 39986927. doi:10.1016/j.annonc.2025.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。